$DARE
Dare Bioscience, Inc.

2020 Q1 Form 10-Q Financial Statement

#000140191420000068 Filed on May 14, 2020

View on sec.gov

Income Statement

Concept 2020 Q1 2019 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.870M $1.390M
YoY Change 34.53% -0.71%
% of Gross Profit
Research & Development $2.380M $1.693M
YoY Change 40.53% 55.84%
% of Gross Profit
Depreciation & Amortization $11.95K $1.150K
YoY Change 939.04%
% of Gross Profit
Operating Expenses $4.254M $3.083M
YoY Change 37.98% -59.84%
Operating Profit -$4.254M -$3.083M
YoY Change 37.98% -59.84%
Interest Expense
YoY Change
% of Operating Profit
Other Income/Expense, Net $1.821K $31.23K
YoY Change -94.17% 165.93%
Pretax Income -$4.250M -$3.050M
YoY Change 39.34% -60.23%
Income Tax
% Of Pretax Income
Net Earnings -$4.252M -$3.052M
YoY Change 39.33% -60.19%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$178.6K -$267.1K
COMMON SHARES
Basic Shares Outstanding 24.69M shares 11.42M shares
Diluted Shares Outstanding

Balance Sheet

Concept 2020 Q1 2019 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $5.050M $3.510M
YoY Change 43.87% -77.54%
Cash & Equivalents $5.047M $3.500M
Short-Term Investments
Other Short-Term Assets $3.840M $590.0K
YoY Change 550.85% 103.45%
Inventory
Prepaid Expenses $3.845M $588.5K
Receivables
Other Receivables $429.7K $166.7K
Total Short-Term Assets $9.322M $4.260M
YoY Change 118.81% -73.28%
LONG-TERM ASSETS
Property, Plant & Equipment $51.58K $8.245K
YoY Change 525.62%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $840.6K $751.3K
YoY Change 11.88% 8.89%
Total Long-Term Assets $892.2K $759.6K
YoY Change 17.45% 10.86%
TOTAL ASSETS
Total Short-Term Assets $9.322M $4.260M
Total Long-Term Assets $892.2K $759.6K
Total Assets $10.21M $5.020M
YoY Change 103.47% -69.81%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.531M $330.0K
YoY Change 364.09% -59.26%
Accrued Expenses $1.691M $690.8K
YoY Change 144.72%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $4.716M $1.016M
YoY Change 363.93% 25.86%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $284.2K $223.0K
YoY Change 27.42%
Total Long-Term Liabilities $284.2K $223.0K
YoY Change 27.42%
TOTAL LIABILITIES
Total Short-Term Liabilities $4.716M $1.016M
Total Long-Term Liabilities $284.2K $223.0K
Total Liabilities $7.000M $1.239M
YoY Change 464.73% 52.93%
SHAREHOLDERS EQUITY
Retained Earnings -$48.30M -$32.02M
YoY Change 50.84% 60.94%
Common Stock $51.62M $35.89M
YoY Change 43.81% 0.4%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $3.214M $3.780M
YoY Change
Total Liabilities & Shareholders Equity $10.21M $5.020M
YoY Change 103.47% -69.82%

Cashflow Statement

Concept 2020 Q1 2019 Q1
OPERATING ACTIVITIES
Net Income -$4.252M -$3.052M
YoY Change 39.33% -60.19%
Depreciation, Depletion And Amortization $11.95K $1.150K
YoY Change 939.04%
Cash From Operating Activities -$6.598M -$3.308M
YoY Change 99.41% 56.14%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities $6.888M $0.00
YoY Change -100.0%
NET CHANGE
Cash From Operating Activities -$6.598M -$3.308M
Cash From Investing Activities
Cash From Financing Activities $6.888M $0.00
Net Change In Cash $267.2K -$3.301M
YoY Change -108.1% -140.93%
FREE CASH FLOW
Cash From Operating Activities -$6.598M -$3.308M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020Q1 dare Adjustments To Additional Paid In Capital Common Stock And Warrants Issued Shares
AdjustmentsToAdditionalPaidInCapitalCommonStockAndWarrantsIssuedShares
1699000 shares
CY2019Q4 dare Deferred Grant Funding Current
DeferredGrantFundingCurrent
2019674 USD
CY2020Q1 dare Deferred Grant Funding Current
DeferredGrantFundingCurrent
1089064 USD
CY2019Q1 dare Increase Decrease In Deferred Grant Funding
IncreaseDecreaseInDeferredGrantFunding
0 USD
CY2020Q1 dare Increase Decrease In Deferred Grant Funding
IncreaseDecreaseInDeferredGrantFunding
930610 USD
CY2019Q1 dare Increase Decrease In Other Non Current Assets And Deferred Charges
IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges
-55233 USD
CY2020Q1 dare Increase Decrease In Other Non Current Assets And Deferred Charges
IncreaseDecreaseInOtherNonCurrentAssetsAndDeferredCharges
-38682 USD
CY2019Q1 dare License Fee
LicenseFee
112500 USD
CY2020Q1 dare License Fee
LicenseFee
12500 USD
CY2019Q1 dare Net Proceeds From Issuance Of Common Stock And Warrants
NetProceedsFromIssuanceOfCommonStockAndWarrants
0 USD
CY2020Q1 dare Net Proceeds From Issuance Of Common Stock And Warrants
NetProceedsFromIssuanceOfCommonStockAndWarrants
5222687 USD
CY2019Q1 dare Non Cash Lease Expense
NonCashLeaseExpense
419 USD
CY2020Q1 dare Non Cash Lease Expense
NonCashLeaseExpense
-55786 USD
CY2019Q1 dare Number Of Common Stock Warrants Exercised
NumberOfCommonStockWarrantsExercised
0 shares
CY2020Q1 dare Number Of Common Stock Warrants Exercised
NumberOfCommonStockWarrantsExercised
3 shares
CY2018Q1 dare Percentage Of Aggregate Commission
PercentageOfAggregateCommission
0.03
CY2020Q1 dare Periodof Insufficient Cashand Liquidity Requirements
PeriodofInsufficientCashandLiquidityRequirements
P12M
CY2019Q1 dare Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
0 USD
CY2020Q1 dare Proceeds From Issuance Of Common Stock And Warrants
ProceedsFromIssuanceOfCommonStockAndWarrants
1665020 USD
CY2020Q1 dare Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Forfeiture Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsForfeitureRate
0.00
CY2020Q1 dare Weighted Average Amortization Period
WeightedAverageAmortizationPeriod
P2Y10M24D
CY2020Q1 dei Amendment Flag
AmendmentFlag
false
CY2020Q1 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2020Q1 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
1690626 USD
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-102625 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
160841 USD
CY2020Q1 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-125569 USD
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
44564674 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1083183 USD
CY2020Q1 us-gaap Accounts Payable Current
AccountsPayableCurrent
1531497 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2098653 USD
CY2020Q1 dei Document Period End Date
DocumentPeriodEndDate
2020-03-31
CY2020Q1 dei Document Type
DocumentType
10-Q
CY2020Q1 dei Entity Central Index Key
EntityCentralIndexKey
0001401914
CY2020Q2 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
26646191 shares
CY2020Q1 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
CY2020Q1 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020Q1 dei Entity Registrant Name
EntityRegistrantName
Dare Bioscience, Inc.
CY2020Q1 dei Entity Shell Company
EntityShellCompany
false
CY2020Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2020Q1 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
51612721 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
97968 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Warrant Issued
AdjustmentsToAdditionalPaidInCapitalWarrantIssued
1665020 USD
CY2019Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5941193 shares
CY2020Q1 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
4621269 shares
CY2019Q4 us-gaap Assets
Assets
7442788 USD
CY2020Q1 us-gaap Assets
Assets
10213965 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
6443932 USD
CY2020Q1 us-gaap Assets Current
AssetsCurrent
9321811 USD
CY2019Q4 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
1000000 USD
CY2020Q1 us-gaap Business Combination Contingent Consideration Liability Noncurrent
BusinessCombinationContingentConsiderationLiabilityNoncurrent
1000000 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
4780107 USD
CY2020Q1 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
5047325 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
6805889 USD
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
3505026 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
4780107 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
5047325 USD
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-3300863 USD
CY2020Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
267218 USD
CY2020Q1 us-gaap Class Of Warrant Or Right Outstanding
ClassOfWarrantOrRightOutstanding
2034643 shares
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2020Q1 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q1 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000 shares
CY2020Q1 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
120000000 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
19683401 shares
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
334000 USD
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
42000 USD
CY2019Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
59478 USD
CY2020Q1 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
24700553 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
19683401 shares
CY2020Q1 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
24700553 shares
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
1968 USD
CY2020Q1 us-gaap Common Stock Value
CommonStockValue
2470 USD
CY2019Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3044219 USD
CY2020Q1 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-4275192 USD
CY2019Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
0 USD
CY2020Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
1000000 USD
CY2020Q1 us-gaap Deferred Compensation Sharebased Arrangements Liability Current And Noncurrent
DeferredCompensationSharebasedArrangementsLiabilityCurrentAndNoncurrent
1686903 USD
CY2019Q1 us-gaap Depreciation
Depreciation
1150 USD
CY2020Q1 us-gaap Depreciation
Depreciation
11949 USD
CY2019Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.27
CY2020Q1 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.18
CY2019Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
7621 USD
CY2020Q1 us-gaap Effect Of Exchange Rate On Cash And Cash Equivalents
EffectOfExchangeRateOnCashAndCashEquivalents
-22944 USD
CY2019Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1277180 USD
CY2020Q1 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1861765 USD
CY2020Q1 us-gaap Grants Receivable
GrantsReceivable
428000 USD
CY2019Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-134087 USD
CY2020Q1 us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
448314 USD
CY2020Q1 us-gaap Increase Decrease In Accrued Liabilities
IncreaseDecreaseInAccruedLiabilities
-408027 USD
CY2019Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0 USD
CY2020Q1 us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
1000000 USD
CY2019Q1 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
135676 USD
CY2020Q1 us-gaap Increase Decrease In Other Receivables
IncreaseDecreaseInOtherReceivables
-125488 USD
CY2019Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
201129 USD
CY2020Q1 us-gaap Increase Decrease In Prepaid Expense
IncreaseDecreaseInPrepaidExpense
2736149 USD
CY2019Q1 us-gaap Lessee Operating Lease Discount Rate
LesseeOperatingLeaseDiscountRate
0.07
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
739000 USD
CY2020Q1 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
363000 USD
CY2020Q1 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
50000 USD
CY2018Q3 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P1Y
CY2019Q4 us-gaap Liabilities
Liabilities
7001962 USD
CY2020Q1 us-gaap Liabilities
Liabilities
6999782 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
7442788 USD
CY2020Q1 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
10213965 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
5612406 USD
CY2020Q1 us-gaap Liabilities Current
LiabilitiesCurrent
4715582 USD
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
0 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
6887708 USD
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-3308484 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6597546 USD
CY2020Q1 us-gaap Net Cash Provided By Used In Operating Activities Continuing Operations
NetCashProvidedByUsedInOperatingActivitiesContinuingOperations
-6600000 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-3051840 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-4252248 USD
CY2018Q3 us-gaap Net Rentable Area
NetRentableArea
3169 sqft
CY2020Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
CY2019Q1 us-gaap Operating Expenses
OperatingExpenses
3083071 USD
CY2020Q1 us-gaap Operating Expenses
OperatingExpenses
4254069 USD
CY2019Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-3083071 USD
CY2020Q1 us-gaap Operating Income Loss
OperatingIncomeLoss
-4254069 USD
CY2019Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
27000 USD
CY2020Q1 us-gaap Operating Lease Cost
OperatingLeaseCost
76000 USD
CY2020Q1 us-gaap Operating Lease Liability
OperatingLeaseLiability
689000 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
410896 USD
CY2020Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
404395 USD
CY2020Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
404000 USD
CY2020Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
284000 USD
CY2019Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
27000 USD
CY2020Q1 us-gaap Operating Lease Payments
OperatingLeasePayments
128000 USD
CY2020Q1 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y7M10D
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
935325 USD
CY2020Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
840572 USD
CY2019Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
7621 USD
CY2020Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-22944 USD
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
389556 USD
CY2020Q1 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
284200 USD
CY2019Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
31231 USD
CY2020Q1 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
1821 USD
CY2019Q4 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
555210 USD
CY2020Q1 us-gaap Other Receivables Net Current
OtherReceivablesNetCurrent
429722 USD
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2020Q1 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2020Q1 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000 shares
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2020Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-48275439 USD
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
1.21
CY2020Q1 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0 shares
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2020Q1 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0 shares
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q1 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
1108615 USD
CY2020Q1 us-gaap Prepaid Expense Current
PrepaidExpenseCurrent
3844764 USD
CY2019Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
0 USD
CY2020Q1 us-gaap Proceeds From Issuance Or Sale Of Equity
ProceedsFromIssuanceOrSaleOfEquity
1 USD
CY2020Q1 us-gaap Proceeds From Warrant Exercises
ProceedsFromWarrantExercises
1700000 USD
CY2019Q1 us-gaap Profit Loss
ProfitLoss
-3051840 USD
CY2020Q1 us-gaap Profit Loss
ProfitLoss
-4252248 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
63531 USD
CY2020Q1 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
51582 USD
CY2019Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
1693391 USD
CY2020Q1 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
2379804 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-44023191 USD
CY2020Q1 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-48300000 USD
CY2019Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
231698 USD
CY2020Q1 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0 USD
CY2019Q1 us-gaap Share Based Compensation
ShareBasedCompensation
97968 USD
CY2020Q1 us-gaap Share Based Compensation
ShareBasedCompensation
160841 USD
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0086
CY2020Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
1.00
CY2020Q1 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P10Y
CY2020Q1 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
5222687 USD
CY2020Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
1 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
6726620 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
3780369 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
440826 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
3214183 USD
CY2019Q2 us-gaap Warrant Down Round Feature Increase Decrease In Equity Amount
WarrantDownRoundFeatureIncreaseDecreaseInEquityAmount
800000 USD
CY2019Q2 us-gaap Warrant Exercise Price Decrease
WarrantExercisePriceDecrease
0.98
CY2019Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
11422161 shares
CY2020Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
23799396 shares

Files In Submission

Name View Source Status
0001401914-20-000068-index-headers.html Edgar Link pending
0001401914-20-000068-index.html Edgar Link pending
0001401914-20-000068.txt Edgar Link pending
0001401914-20-000068-xbrl.zip Edgar Link pending
dare-20200331.xml Edgar Link completed
dare-20200331.xsd Edgar Link pending
dare-20200331_cal.xml Edgar Link unprocessable
dare-20200331_def.xml Edgar Link unprocessable
dare-20200331_lab.xml Edgar Link unprocessable
dare-20200331_pre.xml Edgar Link unprocessable
darebioinlinefullcolorrgba05.jpg Edgar Link pending
dare_10qx2020x0331.htm Edgar Link pending
ex1013b.htm Edgar Link pending
ex1014b.htm Edgar Link pending
exhibit311_20200331.htm Edgar Link pending
exhibit312_20200331.htm Edgar Link pending
exhibit321_20200331.htm Edgar Link pending
exhibit322_20200331.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending